60-Year-Old Drug May Hold Clues To Stopping Spread Of Breast Cancer

One of the oldest chemotherapy drugs in the world may be able to stop breast cancer spreading, according to a new study.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

Condition:   Stage IV Breast Cancer AJCC v6 and v7 Interventions:   Dietary Supplement: Dietary Intervention;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsor:   Ohio State University Comprehensive Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Objective: Vulvovaginal atrophy (VVA) is a condition frequently observed in menopause. Its symptoms can significantly affect the quality of life of patients. Since VVA is related to estrogen deficiency, chemotherapy and hormone therapy for breast cancer (BC) might cause VVA by inducing menopause. Given the lack of effective treatment for VVA in BC survivors, we retrospectively evaluated the efficacy and tolerability of fractional microablative CO2 laser therapy in these patients. Methods: We treated 82 BC survivors with three cycles of CO2 laser after failure of topical nonestrogenic therapy. The severity of symptoms ...
Source: Menopause - Category: OBGYN Tags: Original Articles Source Type: research
Conclusion ABVS showed ‘good’ correlation with MRI tumour response evaluation in breast cancer patients during NAC with ‘excellent’ inter- and intra-observer agreement. ABVS has patients’ preference over breast MRI and could be considered as alternative to breast MRI, in case results on an on-going prospective trial confirm these results (NTR6799).
Source: European Journal of Radiology - Category: Radiology Source Type: research
Conclusions/Implications for Practice: The FIS has acceptable reliability, content validity, and construct validity. This scale is appropriate for use in research and clinical practice settings to evaluate the risk–benefit perceptions of pregnancy in patients with breast cancer.
Source: Journal of Nursing Research - Category: Nursing Tags: Original Article Source Type: research
Conclusions: This SEER analysis demonstrates that a substantial proportion of women with early stage breast cancer are eligible for HFRT, APBI, or ET alone after breast conserving surgery according to consensus guidelines and prospective trial criteria. With incorporation of additional pathologic, dosimetric, and chemotherapy data, quality assurance pathways may use such data to help ensure patients are receiving appropriate risk stratified treatment recommendations.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
Conclusions: Patients who have had an axillary lymph node dissection and limited node-positive disease may be candidates for treatment with APBI. Further research is ultimately needed to better define specific criteria for APBI in node-positive patients.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Breast Source Type: research
CONCLUSION: Postmenopausal women with HR+/HER2- mBC who have previously failed an NSAI and received palbociclib+fulvestrant, everolimus+AI or everolimus+fulvestrant had longer PFS compared to those who received fulvestrant or AI alone. PMID: 29781326 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
M árcio Debiasi, Carisi A. Polanczyk, Patrícia Ziegelmann, Carlos Barrios, Hongyuan Cao, James J. Dignam, Paul Goss, Brittany Bychkovsky, Dianne M. Finkelstein, Rodrigo S. Guindalini, Paulo Filho, Caroline Albuquerque, Tomás Reinert, Evandro de Azambuja, Olufunmilayo Olopade
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionWe performed and evaluated the proposed PRM method to study and analyze the behavior of a tumor during the first round of chemotherapy, based on the intra-tumor changes of MR breast tumor images. The AUC obtained for the PRM method is considered as relevant in the early prediction of breast tumor response.
Source: International Journal of Computer Assisted Radiology and Surgery - Category: Intensive Care Source Type: research
The β-blocker carvedilol had no impact on left ventricular ejection fraction (LVEF) in women with breast cancer undergoing chemotherapy, found astudy in theJournal of the American College of Cardiology.
Source: JAMA - Category: General Medicine Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Pharmaceuticals | Study